Divergent Regulatory and Reimbursement Pathways for Digital Therapeutics: A Scoping Review With Implications for Korea
INQUIRY: The Journal of Health Care Organization, Provision, and Financing · 2026-03 · 63
DOI: 10.1177/00469580261467451 ↗Kurz gefasst
Scoping Review in der Zeitschrift INQUIRY: The Journal of Health Care Organization, Provision, and Financing, online erschienen am 07.07.2026. Verfasst von Mincheol Kim und 1 weiteren Autor:innen. Beteiligte Einrichtung: Industry-Academic Cooperation Foundation, Keimyung University, Daegu, Republic of Korea. Hauptthemen laut MEDLINE: Reimbursement Mechanisms. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: The National Research Foundation of Korea (NRF) Korean government.
Abstract (Originalsprache)
Introduction
Digital therapeutics (DTx) represent an emerging class of software-based medical devices delivering evidence-based therapeutic interventions. Several countries have developed regulatory and reimbursement frameworks for DTx, while Korea’s evaluation system remains in its early stages. This scoping review compared regulatory and reimbursement frameworks for DTx across the United States, Germany, the United Kingdom, and Korea, and separately derived author-led policy implications for a Korean DTx evaluation framework.
Methods
Following the Arksey and O'Malley framework and PRISMA-ScR guidelines, we searched 11 databases for literature published between January 2015 and December 2025 (final search: 15 February 2026). DTx was operationalized using the Digital Therapeutics Alliance anchor definition with jurisdiction-specific application rules. Data were synthesized along five analytical dimensions: regulation, evidence assessment, reimbursement, postmarket evidence, and governance linkage.
Results
Of 2,847 records, 42 sources (19 articles, 23 policy documents) were included. Jurisdictions diverged most clearly on statutory codification of DTx, the existence of a dedicated reimbursement pathway, and regulator–payer integration. Germany’s DiGA Fast-Track had 61 products listed cumulatively (50 active, 11 removed), exceeding one million prescriptions and €234 million expenditure (GKV-SV reporting period through 31 December 2024). Korea provisionally listed four DTx products since 2023.
Conclusions
Germany’s DiGA system shares more institutional features with Korea’s evolving system than do the US or UK frameworks. We propose, as an author-derived synthesis informed by the review, a five-phase Korean DTx framework, while acknowledging substantive system-level differences (payer pluralism, pricing, benefit design, HTA procedure) that constrain direct transferability.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Industry-Academic Cooperation Foundation, Keimyung University, Daegu, Republic of Korea.
- Department of Ministry, Global Gateway University, Wentzville, MO, USA.
- College of Nursing, Keimyung University, Daegu, Republic of Korea.
ORCID-Profile: Mincheol Kim, Gaeun Kim
Förderung
- The National Research Foundation of Korea (NRF) Korean government
Zitieren
APA
Kim, M., & Kim, G. (2026). Divergent Regulatory and Reimbursement Pathways for Digital Therapeutics: A Scoping Review With Implications for Korea. INQUIRY: The Journal of Health Care Organization, Provision, and Financing, 63. https://doi.org/10.1177/00469580261467451
Vancouver
Kim M, Kim G. Divergent Regulatory and Reimbursement Pathways for Digital Therapeutics: A Scoping Review With Implications for Korea. INQUIRY: The Journal of Health Care Organization, Provision, and Financing. 2026;63. doi:10.1177/00469580261467451
BibTeX
@article{Kim2026,
author = {Kim, Mincheol and Kim, Gaeun},
title = {Divergent Regulatory and Reimbursement Pathways for Digital Therapeutics: A Scoping Review With Implications for Korea},
journal = {INQUIRY: The Journal of Health Care Organization, Provision, and Financing},
year = {2026},
volume = {63},
doi = {10.1177/00469580261467451}
}
EUVIMED